Jordan Hill, PharmD, BCOP, discusses the expanded first-line role of sacituzumab govitecan in metastatic triple-negative breast cancer and how PD-L1 status informs its use alone or with pembrolizumab.
Holistic, integrative, functional, precision—the labels are everywhere, but few patients or clinicians know where one ends and the next begins.
Oncology pharmacy teams can integrate newly approved breast cancer therapies into practice while addressing operational barriers, monitoring requirements, and financial toxicity.
Cassandra Perkey, PharmD, BCOP, explains the operational, staffing, infrastructure, safety, and pharmacist-led requirements for successfully delivering CAR T-cell therapy in a community oncology setting.
GSK's next-generation ROS1 inhibitor earns approval after demonstrating durable responses in the ARROS-1 trial, including among patients with brain metastases.
Cassandra Perkey, PharmD, BCOP, discusses how pharmacists support community CAR T-cell programs through SOP development, treatment planning, education, emergency preparedness, and lessons learned from treating the first patient.
Adding palbociclib to anti-HER2 and endocrine maintenance therapy provides a new treatment option for patients with HR-positive, HER2-positive metastatic breast cancer.
In an interview with Pharmacy Times, Cassandra Perkey, PharmD, BCOP, explains the staffing, infrastructure, hospital partnerships, and scheduling strategies needed to safely deliver outpatient CAR T-cell therapy in a community oncology setting.
Megan May, PharmD, BCOP, FHOPA, FAPO, discusses unanswered questions surrounding antibody-drug conjugate sequencing, biomarker testing, and medication safety in personalized breast cancer care.
Antibody-drug conjugates, evolving HER2 guidelines, and biomarker-driven treatment decisions are transforming breast cancer care and expanding the oncology pharmacist’s role.
A large US registry analysis found that men were more likely than women to be diagnosed with regional or distant disease across 20 nonreproductive cancer sites.
In an interview with Pharmacy Times, Manale Maksour, PharmD, BCOP, BCPS, discussed the patient selection, standardized workflows, toxicity management, payer coordination, and caregiver education needed to safely move bispecific step-up dosing into the outpatient setting.
In an interview with Pharmacy Times, Cassandra Perkey, PharmD, BCOP, outlines the essential teams, SOPs, financial planning, and safety protocols community oncology practices need to launch outpatient CAR T-cell therapy successfully.
In an interview with Pharmacy Times, Cherise Steib, PharmD, HDDP, discussed patient selection, caregiver requirements, cytokine release syndrome (CRS), immune effector cell–associated neurotoxicity syndrome (ICANS), and the American Oncology Network’s approach to building an outpatient bispecific therapy program.
In an interview with Pharmacy Times, Steib explains how structured monitoring, patient education, emergency protocols, and pharmacist involvement support the safe delivery of outpatient bispecific therapy.
Cherise Steib, PharmD, HDDP, discusses how bispecific therapies expand treatment options and the factors that determine whether patients are appropriate candidates for outpatient administration.
Baseline proton pump inhibitor (PPI) use and, to a lesser extent, antibiotic use were associated with reduced benefit from consolidation durvalumab after chemoradiotherapy in patients with unresectable stage 3 NSCLC.
This week's episode tracks the growing nationwide cyclosporiasis outbreak and its link to lettuce, a new Utah pilot using artificial intelligence to authorize prescription refills, and FDA approvals in Alzheimer disease, precision oncology, and metastatic breast cancer.
In an interview with Pharmacy Times, Maksour explained how payer restrictions on prophylactic tocilizumab and the need for intensive patient and caregiver education can influence the safety and feasibility of outpatient bispecific therapy.
Patients with cancer on semaglutide or tirzepatide face hidden drug-drug interactions such as slowed absorption and nausea, requiring antiemetics and pharmacist coordination.
Outpatient BiTE therapy for multiple myeloma may be safely supported in community oncology settings through careful patient selection, pharmacist-led coordination, home monitoring, caregiver education, and standardized protocols for managing CRS and ICANS.
Compared with conventional imaging alone, patient-reported outcomes integrated with machine learning may provide an earlier indication of breast cancer recurrence, disease progression, and survival.
In an interview with Pharmacy Times, Nicole McMullin, regional clinical pharmacist at American Oncology Network, discussed AON’s development of an all-outpatient approach to step-up dosing for bispecific T-cell engager therapy in multiple myeloma.
In an interview with Pharmacy Times, Manale Maksour, PharmD, BCOP, BCPS, associate director of pharmacy services at American Oncology Network, discusses the growing use of outpatient step-up dosing for bispecific T-cell engager therapies and the operational challenges clinics must address to safely implement these programs.
The approval of the drug combination is supported by findings from the phase 3 VIKTORIA-1 clinical trial.
Selpercatinib received approval for adults and children 2 years and older with previously treated or treatment-refractory RET fusion–positive solid tumors.
Andrew Li, PharmD, BCOP, discusses key targeted therapy updates in the 2026 ASCO living guideline for stage IV non–small cell lung cancer and how pharmacists can help manage treatment-related toxicities and access barriers.
This week's episode covers a multistate rise in cyclosporiasis infections, insights from a Yale psychiatrist on safety monitoring for psychedelic therapies, and a wave of FDA approvals spanning nephrology, gene therapy, and cell therapy—plus a major expansion of the NIH's All of Us Research Program.
Utah's AI-powered prescription refill pilot is fueling debate over how artificial intelligence can improve medication access and workflow efficiency while preserving the clinical oversight needed to ensure patient safety.
The regimens are pembrolizumab plus enfortumab vedotin-ejfv (EV) and pembrolizumab with berahyaluronidase alfa-pmph and EV.
